The Use of Dental Pulp Tissue as an Autogenous Graft for Ridge Augmentation
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03943849 |
|
Recruitment Status :
Withdrawn
(Lack of funding)
First Posted : May 9, 2019
Last Update Posted : February 3, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Tooth Loss | Other: Particulate bone graft Other: Autogenous dental pulp tissue Other: Resorbable collagen membrane Other: Suture | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 0 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | The Use of Dental Pulp Tissue as an Autogenous Graft for Ridge Augmentation |
| Estimated Study Start Date : | May 1, 2023 |
| Estimated Primary Completion Date : | September 1, 2025 |
| Estimated Study Completion Date : | September 1, 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Particulate bone graft plus autogenous dental pulp tissue
Dental pulp will be isolated from teeth extracted for non-periodontal reasons chairside. The isolated dental pulp will be mixed with hydrated particulate bone graft, and the mixture will be placed in the debrided extraction socket. The socket will be covered by a resorbable collagen membrane and sutured.
|
Other: Particulate bone graft
Creos allo.gain allogenic bone particulate mineralized cortical bone will be hydrated and placed in the extraction socket.
Other Names:
Other: Autogenous dental pulp tissue Dental pulp will be isolated from teeth extracted for non-periodontal reasons chairside, mixed with hydrated particulate bone graft, and then placed in the extraction socket. Other: Resorbable collagen membrane After placement of particulate bone graft or particulate bone graft plus autogenous dental pulp tissue, socket will be covered by a resorbable collagen membrane and sutured. Other: Suture Resorbable or non-resorbable suture material |
|
Active Comparator: Particulate bone graft
Hydrated particulate bone graft will be placed in the debrided extraction socket. The socket will be covered by a resorbable collagen membrane and sutured.
|
Other: Particulate bone graft
Creos allo.gain allogenic bone particulate mineralized cortical bone will be hydrated and placed in the extraction socket.
Other Names:
Other: Resorbable collagen membrane After placement of particulate bone graft or particulate bone graft plus autogenous dental pulp tissue, socket will be covered by a resorbable collagen membrane and sutured. Other: Suture Resorbable or non-resorbable suture material |
- Bone fill as assessed by radiograph [ Time Frame: immediately after placement of bone graft ]
- Bone fill as assessed by radiograph [ Time Frame: 2 months after placement of bone graft ]
- Bone fill as assessed by radiograph [ Time Frame: 4 months after placement of bone graft ]
- Extent of mineralization as assessed by von Kossa staining [ Time Frame: 4 months after placement of bone graft ]
- Extent of mineralization as assessed by Xylenol Orange staining [ Time Frame: 4 months after placement of bone graft ]
- Expression of osteoblastic marker Bsp assessed by quantitative PCR (qPCR) [ Time Frame: 4 months after placement of bone graft ]
- Expression of osteoblastic marker BSP assessed by immunostaining using anti-BSP antibody [ Time Frame: 4 months after placement of bone graft ]
- Expression of osteoblastic marker Bglap assessed by quantitative PCR (qPCR) [ Time Frame: 4 months after placement of bone graft ]
- Expression of osteoblastic marker BGLAP assessed by immunostaining using anti-BGLAP antibody [ Time Frame: 4 months after placement of bone graft ]
- Expression of osteoblastic marker Dmp1 assessed by quantitative PCR (qPCR) [ Time Frame: 4 months after placement of bone graft ]
- Expression of osteoblastic marker DMP1 assessed by immunostaining using anti-DMP1 antibody [ Time Frame: 4 months after placement of bone graft ]
- Expression of osteoblastic marker Col1a1 assessed by quantitative PCR (qPCR) [ Time Frame: 4 months after placement of bone graft ]
- Expression of osteoblastic marker Sost assessed by quantitative PCR (qPCR) [ Time Frame: 4 months after placement of bone graft ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- American Society of Anesthesiologists (ASA) Physical Status Classification System ASA 1 (A normal healthy patient) or ASA 2 (A patient with mild systemic disease)
- never smoker
- patients with planned tooth extraction
- intact extraction sockets
- no medication or antibiotics intake for at least 6 months prior to the procedure
- patients who gave their consent to participate in the study.
Exclusion Criteria:
- vulnerable subjects (children, pregnant and lactating women, patients with learning disabilities, and prisoners)
- inability to obtain pulp tissue (for example, due to previous endodontic therapy, obliterated pulp canals)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03943849
| United States, Texas | |
| The University of Texas Health Science Center at Houston | |
| Houston, Texas, United States, 77030 | |
| Principal Investigator: | Karo Parsegian, DMD, MDSc, PhD | The University of Texas Health Science Center, Houston |
| Responsible Party: | Karo Parsegian, Assistant Professor, The University of Texas Health Science Center, Houston |
| ClinicalTrials.gov Identifier: | NCT03943849 |
| Other Study ID Numbers: |
HSC-DB-18-0873 |
| First Posted: | May 9, 2019 Key Record Dates |
| Last Update Posted: | February 3, 2022 |
| Last Verified: | January 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Bone graft Tooth extraction Dental pulp |
|
Tooth Loss Periodontal Diseases Mouth Diseases Stomatognathic Diseases Tooth Diseases |

